P1/2, N=360, Recruiting, BioNTech SE | Trial completion date: Feb 2030 --> Jul 2027 | Trial primary completion date: Feb 2030 --> Jul 2027

P1, N=168, Recruiting, BioAtla, Inc. | Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2025 --> Jun 2025

P3, N=270, Recruiting, Wuhan YZY Biopharma Co., Ltd.

P2, N=80, Active, not recruiting, Wuhan YZY Biopharma Co., Ltd.

EPCAM was upregulated in lung metastases of leiomyosarcoma, suggesting inhibition of CD8 T cell migration. Our findings suggest that EPCAM could serve as a potential novel therapeutic target for leiomyosarcoma.

P1, N=94, Not yet recruiting, ITabMed Co., Ltd.

In a murine model, an Fc-inert EpCAMx4-1BB bsAb promoted antitumor activity in vivo. It is intended to investigate the clinical safety and preliminary antitumor activity of DuoBody-EpCAMx4-1BB in patients with solid tumors in a first-in-human trial.

P1, N=38, Recruiting, AcadeMab Biomedical Inc. | Not yet recruiting --> Recruiting

In contrast, analogous treatment with equimolar amounts of EpCAM/CD3-directed bispecific T-cell engager solitomab resulted in a massive release of IFNγ, a feature commonly associated with adverse cytokine-release syndrome. Combinatorial treatment with EpCAM-ReTARG and EGFR-ReTARG strongly potentiated selective cancer cell elimination owing to the concerted action of the corresponding cognate anti-CMV CD8 T cell clones. In conclusion, ReTARG fusion proteins may be useful as an alternative or complementary form of targeted cancer immunotherapy for 'cold' solid cancers.

Catumaxomab is a trifunctional antibody intraperitoneal (IP) immunotherapy authorized in Europe that can be used to diminish malignant ascites by targeting EpCAM...This reaction was strengthened by anti-PD-L1 or anti-Gr1. When paired with CD137 co-stimulatory signaling, CAR-T cells for folate receptor cancers made it easier for T-cell tumors to find their way to and stay alive in the body.

Tx 50 μg 01-04 pTaG3Tis CAT pTis CR CR CR CR CR BCG 01-05 pTaG2Tis CAT CR CR pTaG2 recurrence CR pTaG2 recurrence decl. 01-06 pTaG3Tis CAT pTaG3Tis Tis pTaG3Tis recurrence CR CR BCG 70 μg 01-07 pTaG3 CAT CR CR CR CR BCG 01-08 pTaG3Tis CAT CR CR CR CR BCG 01-09 pT1G3Tis CAT CR CR CR CR 01-10 pT1G3TaG2 CAT CR CR CR 100 μg 01-12 pT1G3 CAT CR CR 01-13 pTaG3 CAT CR CR 02-01 pT1 CAT CR CR CAT, Catumaxomab; CR, complete remission; BCG, Bacille Calmuette Guerin; decl, declined

Moreover, α-EpCAM IT significantly reduced tumor size in vivo study. The achieved results indicate the potential of designing α-EpCAM IT as a novel therapeutic for cancer therapy.

P1/2, N=96, Not yet recruiting, Wuhan YZY Biopharma Co., Ltd.

P1, N=30, Recruiting, Lindis Biotech GmbH | Trial primary completion date: Dec 2021 --> Dec 2022

We further confirmed this conclusion with the activator (Rapamycin, RAP) and inhibitor (Wortmannin) of autophagy...These findings represent a novel mechanism by which deglycosylated EpCAM inhibits proliferation by enhancing autophagy of breast cancer cells via PI3K/Akt/mTOR pathway. In conclusion, the combination of autophagy modulation and EpCAM targeted therapy is a promising therapeutic strategy in the treatment of breast cancer.

P1, N=27, Not yet recruiting, Michael Gunn | Trial completion date: Dec 2022 --> Mar 2024 | Initiation date: Dec 2021 --> Mar 2022 | Trial primary completion date: Dec 2021 --> Dec 2022

P1, N=27, Not yet recruiting, Michael Gunn | Initiation date: Sep 2021 --> Dec 2021

Targeting EZH2 by Compound 30 has potential use in the treatment of cancer especially hepatocellular carcinoma.

Interestingly, response to OXPHOS inhibition by metformin and IACS010759 in tumor spheroids correlated with the extent of mitochondrial membrane potential measured by fluorescence-activated cell sorting (FACS). Our data contribute to a better understanding of the biology of ovarian cancer spheroids and identify the OXPHOS pathway as new potential treatment option in advanced ovarian cancer.

This finding indicated that a combination of immunotherapy strategies, such as ILT-4 blockade, could improve the clinical outcomes in patients with cancer. Moreover, multicolor flow cytometry can be employed as a reliable and efficient, alternative to immunohistochemistry, for evaluating the immune checkpoint proteins expressed in tumor lesions.

Our study also provides clinical evidence for the beneficial effect of the PD-1 inhibitor pembrolizumab for CRC patients that exhibit cytoplasmic MSH2 staining. Our study demonstrates that the rare cytoplasmic MSH2 staining pattern should be fully recognized by pathologists and geneticists. Given the specific genotype-phenotype correlation in LS screening, we advocate that all CRC patients with cytoplasmic MSH2 staining in histology should be screened for LGRs of EPCAM and MSH2.

This is of particular importance since the long-term goals of lung cancer surgery include improved length and quality of life, and surgical intervention is not always an option. Conclusion Obtaining reliable readouts from blood can provide crucial information for disease progression, as well as being of prognostic value, monitoring patients’ response to treatment.

CM enrichment perfectly integrates with the DA/Ampli1 workflow for single CTC molecular analysis but CM enriched cells are also available for other downstream applications to investigate cancer heterogeneity. *For the full intended use see https://documents.cellsearchctc.com/

This is of particular importance since the long-term goals of lung cancer surgery include improved length and quality of life, and surgical intervention is not always an option. Conclusion Obtaining reliable readouts from blood can provide crucial information for disease progression, as well as being of prognostic value, monitoring patients’ response to treatment.

CM enrichment perfectly integrates with the DA/Ampli1 workflow for single CTC molecular analysis but CM enriched cells are also available for other downstream applications to investigate cancer heterogeneity. *For the full intended use see https://documents.cellsearchctc.com/

CM enrichment perfectly integrates with the DA/Ampli1 workflow for single CTC molecular analysis but CM enriched cells are also available for other downstream applications to investigate cancer heterogeneity. *For the full intended use see https://documents.cellsearchctc.com/

CM enrichment perfectly integrates with the DA/Ampli1 workflow for single CTC molecular analysis but CM enriched cells are also available for other downstream applications to investigate cancer heterogeneity. *For the full intended use see https://documents.cellsearchctc.com/

This is of particular importance since the long-term goals of lung cancer surgery include improved length and quality of life, and surgical intervention is not always an option. Conclusion Obtaining reliable readouts from blood can provide crucial information for disease progression, as well as being of prognostic value, monitoring patients’ response to treatment.

This is of particular importance since the long-term goals of lung cancer surgery include improved length and quality of life, and surgical intervention is not always an option. Conclusion Obtaining reliable readouts from blood can provide crucial information for disease progression, as well as being of prognostic value, monitoring patients’ response to treatment.